1996
DOI: 10.1159/000227624
|View full text |Cite
|
Sign up to set email alerts
|

Granulocyte-Macrophage-Colony-Stimulating Factor Support in Patients with Acute Non-Lymphatic Leukemia

Abstract: Forty-one patients with acute non-lymphoblastic leukemia were treated between March 1990 and November 1993 with mitoxantrone, cytarabine, etoposide and granulocyte-macrophage-colony-stimulating factor (GM-CSF) started on day 1. This was given as induction, consolidation and intensification treatment. A complete response was obtained in 26 of 41 (63%) patients. The median survival of the 25 evaluable patients in complete remission was 18 months. The median duration to neutropenia < 500/ul was 20 days during ind… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2000
2000
2001
2001

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 9 publications
(10 reference statements)
0
1
0
Order By: Relevance
“…GM‐CSF is currently employed for the reversal of neutropenia associated with cytotoxic chemotherapy, and haematopoietic stem cell transplantation. 28–30 Side‐effects include fever, chills, myalgia, headache, decreased appetite and nausea. As we have just shown, GM‐CSF primes macrophages for an enhanced TNF‐α and IL‐6 response to LPS.…”
Section: Discussionmentioning
confidence: 99%
“…GM‐CSF is currently employed for the reversal of neutropenia associated with cytotoxic chemotherapy, and haematopoietic stem cell transplantation. 28–30 Side‐effects include fever, chills, myalgia, headache, decreased appetite and nausea. As we have just shown, GM‐CSF primes macrophages for an enhanced TNF‐α and IL‐6 response to LPS.…”
Section: Discussionmentioning
confidence: 99%